Updated Results Confirm Benefits of Adjuvant Pembrolizumab for Advanced Melanoma Are Sustained

Web Exclusives - Melanoma

Adjuvant treatment with pembrolizumab (Keytruda) extended distant metastasis-free survival (DMFS) compared with placebo following complete resection of high-risk, stage III melanoma, according to updated, long-term follow-up from the EORTC 1325/KEYNOTE-054 clinical trial. Long-term follow-up also confirmed a sustained benefit of pembrolizumab on the end point of recurrence-free survival (RFS), the study’s primary end point.

Compared with placebo, pembrolizumab also decreased the incidence of distant metastasis as a first recurrence and locoregional-only recurrence.

The updated analyses were presented at the virtual ESMO 2020 Congress by Alexander M.M. Eggermont, MD, PhD, Chief Scientific Officer, Pediatric Oncology, Princess Máxima Center, Utrecht, Netherlands.

DMFS was a secondary end point of the double-blind, phase 3 EORTC 1325/KEYNOTE-054 trial. The primary analysis showed that pembrolizumab improved RFS (hazard ratio [HR], 0.57; P ˂.0001) compared with placebo at a median follow-up of 1.25 years, and led to approval of pembrolizumab as adjuvant treatment for patients with high-risk, stage III melanoma by the US Food and Drug Administration and the European Medicines Agency.

EORTC 1325/KEYNOTE-054 included 1019 patients who underwent complete resection of cutaneous melanoma metastatic to the lymph nodes and were randomized to either pembrolizumab (200 mg) or placebo every 3 weeks for approximately 1 year (18 doses).

In this latest update of results, the researchers found that after a median 3.5-year follow-up (418 DMFS events), pembrolizumab significantly increased DMFS compared with placebo—65.3% versus 49.4% (HR, 0.60; P <.0001). A similar advantage to pembrolizumab on DMFS was observed in the 853 patients with PD-L1–positive tumors (HR, 0.61; P <.0001). The improvement in DMFS with pembrolizumab was similar when assessed by the American Joint Committee on Cancer (AJCC)-7 stage. Pembrolizumab was superior to placebo on DMFS in patients with AJCC-7 stage IIIA disease (80.8% vs 70.8%; HR, 0.63; P = .169), stage IIIB disease (68.1% vs 51.0%; HR, 0.58; P <.001), and stage IIIC disease (55.8% vs 39.2%; HR, 0.61; P <.001).

The favorable effect of pembrolizumab on DMFS was evident in patients with PD-L1–negative tumors, with a DMFS of 58.0% in the pembrolizumab group versus 40.2% in the placebo group (HR, 0.49; P = .008), as well as in those with PD-L1–positive tumors (66.7% vs 51.6%; HR, 0.61; P <.001). In the 440 patients with BRAF-mutated disease, DMFS was 63.7% with pembrolizumab versus 43.4% with placebo (HR, 0.53; P ˂.001). In those with BRAF wild-type disease, DMFS rates were 62.1% versus 51.4%, respectively (HR, 0.73; P = .035).

An updated RFS analysis showed that at a median of 3.5 years, RFS rates were 59.8% in the pembrolizumab arm and 41.4% in the placebo arm (HR, 0.59; P <.001) in the intent-to-treat population. Pembrolizumab compared with placebo decreased the 3.5-year incidence of distant metastasis as first recurrence (24.9% vs 39.5%; HR, 0.57; P <.0001) and the rate of locoregional-only recurrence (14.0% vs 18.9%; HR, 0.73, P = .05).

In comparison with placebo, pembrolizumab demonstrated significant improvement in DMFS, a sustained RFS benefit, and decreased incidence of recurrence over 3.5 years.

Related Items
Real-World Analysis Finds That Dabrafenib/Trametinib Combination Is Effective in Patients with BRAF V600-Mutated Melanoma with Brain Metastases
Web Exclusives published on December 14, 2020 in Melanoma
Effectiveness of Dual Immunotherapy Confirmed for Patients with Metastatic Melanoma and Autoimmune Disease
Web Exclusives published on December 14, 2020 in Melanoma
Symptoms from Immunotherapy/Targeted Therapy Most Mentioned Topic by Patients with Melanoma on Health-Related Social Media
Web Exclusives published on December 14, 2020 in Melanoma
Complete Responses Equally Durable with Shorter versus Longer Immunotherapy Courses in Advanced Melanoma
Web Exclusives published on December 14, 2020 in Melanoma
Combination Ipilimumab/Nivolumab Better Than Single-Agent Anti–PD-1 Regardless of BRAF Status in Advanced Melanoma
Web Exclusives published on December 14, 2020 in Melanoma
Meaningful Response Possible with Third-Line Targeted Therapy Rechallenge for Patients with BRAF-Mutation–Positive Advanced Melanoma
Web Exclusives published on November 24, 2020 in Melanoma
Immune-Related Adverse Events Occurring After 2 Years of Anti–PD-1 Therapy Are Common
Web Exclusives published on November 24, 2020 in Melanoma
CheckMate-238 Update: Nivolumab Improves 4-Year Relapse-Free Survival in Patients with Advanced Melanoma
Web Exclusives published on November 24, 2020 in Melanoma
Dabrafenib plus Trametinib Confers Long-Term Relapse-Free Benefit in Stage III BRAF-Mutant Melanoma
Web Exclusives published on November 24, 2020 in Melanoma
Noteworthy Numbers: Melanoma
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Melanoma, Noteworthy Numbers
Last modified: November 24, 2020